Navigation Links
Insmed Announces First Quarter 2011 Financial Results
Date:5/10/2011

MONMOUTH JUNCTION, N.J., May 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

Key Recent Highlights:

  • Received Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) Application to conduct a primary efficacy study for ARIKACE® (liposomal amikacin for inhalation) in non-tuberculous mycobacterial (NTM) lung disease
  • Filed for orphan drug status with FDA for ARIKACE® to treat NTM lung infections
  • Received acceptance of abstract for oral presentation of six cycles of data from the open-label study of ARIKACE® in the treatment of cystic fibrosis (CF) patients with Pseudomonas lung infections, at the European Cystic Fibrosis Conference in Hamburg, Germany in June
  • Executed a one-for-10 reverse stock split and regained compliance with Nasdaq's minimum bid price rule
  • Relocated corporate headquarters from Richmond, VA to Monmouth Junction, NJ

  • "The first several months of the year have produced multiple successes for Insmed," said Timothy Whitten, Insmed's President and CEO.  "In particular, we have reached several key milestones related to our development plan for ARIKACE®, including, most recently, the clearance of ARIKACE® to proceed to a primary efficacy study based on our NTM IND filing, and the submission in the U.S. of the ARIKACE® NTM orphan drug designation.  We continue to ramp up our ARIKACE® clinical trial and drug manufacturing activity and remain on schedule to begin enrollment of our Phase 3 clinical trials for ARIKACE® in patients who have NTM lung infections and in CF patients who have Pseudomonas lung infections, in the second half of this year.  In addition, we have regained compliance with Nasdaq's minimum bid price rule and we remain on solid financial ground, with a strong overall cash bala
    '/>"/>

    SOURCE Insmed Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Insmed to Host 2011 First Quarter Earnings Conference Call
    2. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
    3. One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
    4. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
    5. Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
    6. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
    7. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
    8. Insmed to Host Third Quarter 2010 Conference Call
    9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
    10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
    11. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
    (Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
    (Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
    Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
    ... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
    ... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
    Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
    (Date:7/6/2015)... ... July 06, 2015 , ... Invitation to ... yet there is a large gap between the unmet health priorities in the ... health outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone ...
    (Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
    (Date:7/6/2015)... , ... July 06, 2015 , ... ... reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, the only ... expertise with their Top 10 Tips for ICD-10. The ten tips are timely ...
    (Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest ... with Woodbridge Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings ... Screenings are affordable and accurate and run about an hour long with same ...
    (Date:7/6/2015)... ... July 06, 2015 , ... Seedstock today announced Pierre ... address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the Small ... , held at the University of California-San Diego, will explore solutions and methodologies that ...
    Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4
    ... Sciences is launching an action tank, with start-up funds from ... the most promising strategies against global health crises. The Gates ... phase. , The new team, called the Global Health ... executive director of the Global Fund to Fight AIDS, TB ...
    ... headache and watery eyes,are often attributed to the common ... to the American Academy of Allergy, Asthma &,Immunology (AAAAI)., ... a cold during the,winter months when they,re actually experiencing ... Committee. "Cold and,allergy symptoms can be very similar, making ...
    ... are far more likely to be infected with Hepatitis ... often do not get treatment for their liver disease ... , Against this epidemiological background, the article by ... patients, represents an important study in the field, write ...
    ... the hallmark of Alzheimer,s disease, are clumps of ... this devastating neurodegenerative disease. , While effective ... University of Illinois at Chicago chemists suggests a ... professor of chemistry, and his students managed to ...
    ... to discuss new Medicaid generic prescription drug,reimbursement rule and ... his,power to make sure the legislative fix is considered ... be fully implemented in early,2008, will grossly underpay pharmacists ... Brad Hall, Executive Director of the Kentucky Pharmacists Association, ...
    ... CHARLES TOWN, W.Va., Dec. 3 ReBuilder Medical,Technologies, ... the art,electronic devices for diabetic peripheral neuropathy, Molluscum,Contagiosum, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ), "Corporate ... Daena,Carter, CFO of RBRM. "Full disclosure will be ...
    Cached Medicine News:Health News:UCSF launches 'action tank' to advance promising global health strategies 2Health News:Your Stuffy Nose Could Mean More Than a Cold 2Health News:Treating patients with psychiatric disorders for hepatitis C 2Health News:UIC chemists characterize Alzheimer's neurotoxin structure 2Health News:Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule 2Health News:ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October 2
    ... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
    Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
    ... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
    e-MDs Bill practice management system is used in the medical billing cycle....
    Medicine Products: